## SURVIVAL BENEFIT WITH VEMURAFENIB IN 'BRAF' MUTATION POSITIVE MELANOMA: AREA UNDER THE CURVE BASED REANALYSIS **DI-063**

S. FENIX-CABALLERO, J. Diaz-Navarro, M. Camean-Castillo, E.J. Alegre-del Rey, C. Palomo-Palomo, M.A. Blanco-Castaño, J.M. Borrero-Rubio, M.J. Gandara-LadronDeGuevara<sup>1</sup>, J.C. GarciaDeParedes-Esteban<sup>1</sup>, D. Gil-Sierra<sup>1</sup>.

Puerto Real Universitary Hospital, Spain

### BACKGROUND

McArthur et al. (1) recently reported the results of vemurafenib in BRAF mutation-positive melanoma vs. dacarbazine. Difference between medians in overall survival (OS) was 3.9 months (13.6 vs. 9.7, respectively).

However, given the shape of the curves, difference in median survival (DMS) may not provide a good estimate of the survival benefit.

(1) McArthur GA, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323-32.

#### **PURPOSE**


To **reanalyze** the survival benefit of vemurafenib in melanoma from the OS curves using an area-under-curves (AUC) based method.

#### MATERIALS AND METHODS

Kaplan-Meier OS	METHOD	GRAPHICAL	Graphical AUC was applied compared to DMS.
curve	According to a previously published method	AUC	AUC method quantifies the difference between areas, and the results are expressed in time units.

Alegre-DelRey E.J., et al. Area-based measures for assessing survival benefit in Kaplan-Meier's curves. ESMO Congress, Amsterdam 2013. URL: http://eccamsterdam2013.ecco-org.eu/scientific-programme/searchable-programme.aspx#anchorScpr (accessed 14/10/2014).

#### **RESULTS**



# **CONCLUSIONS**

AUC-based analysis showed a shorter survival benefit than the difference in median survival.

This is probably related to the shape of the curves, which diverged at the medium zone of the graph.

